The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Medical Management of Levodopa-Associated Motor Complications in Patients with Parkinson???s Disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110
Non-motor symptoms of Parkinson's disease: diagnosis and management
Chaudhuri, K. R., Healy, D. G., & Schapira, A. H. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70373-8 · Cited by 2,807
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
Alzheimer's Disease and Parkinson's Disease
Nussbaum, R. L., & Ellis, C. E. (2003) · New England Journal of Medicine · doi:10.1056/nejm2003ra020003 · Cited by 1,351
Research works printed but not linked: 70
- Samii, 2004, Lancet, 363, 1783, 10.1016/S0140-6736(04)16305-8 · DOI · Paper page
- Hampton, 2005, JAMA, 293, 149, 10.1001/jama.293.2.149 · doi:10.1001/jama.293.2.149
- Olanow, 2004, Mov Disord, 19, 997, 10.1002/mds.20243 · DOI · Paper page
- Stacy, 2005, Mov Disord, 20, 726, 10.1002/mds.20383 · DOI · Paper page
- Stacy, 2006, Clin Neuropharmacol, 29, 312, 10.1097/01.WNF.0000232277.68501.08 · DOI
- Chapuis, 2005, Mov Disord, 20, 224, 10.1002/mds.20279 · DOI · Paper page
- Rascol, 2005, Lancet, 365, 947, 10.1016/S0140-6736(05)71083-7 · DOI · Paper page
- Jankovic, 2006, Mt Sinai J Med, 73, 682
- Kurth, 1997, Drugs Aging, 10, 332, 10.2165/00002512-199710050-00002 · DOI
- Stocchi, 2005, Arch Neurol, 62, 905, 10.1001/archneur.62.6.905 · DOI · Paper page
- Nilsson, 1998, Acta Neurol Scand, 97, 175, 10.1111/j.1600-0404.1998.tb00633.x · DOI
- Rao, 2006, Am Fam Physician, 74, 2046
- Allain, 2000, Eur Neurol, 44, 22, 10.1159/000008188 · DOI
- Churchyard, 1997, J Neurol Neurosurg Psychiatry, 63, 228, 10.1136/jnnp.63.2.228 · DOI
- Waters, 2004, Mov Disord, 19, 426, 10.1002/mds.20036 · DOI
- Guttman, 2003, CMAJ, 168, 293
- Churchyard, 1999, Mov Disord, 14, 246, 10.1002/1531-8257(199903)14:2<246::AID-MDS1008>3.0.CO;2-P · doi:10.1002/1531-8257(199903)14:2<246::aid-mds1008>3.0.co;2-p
- 2005, Arch Neurol, 62, 241, 10.1001/archneur.62.2.241 · DOI · Paper page
- Radad, 2005, Pharmacol Rep, 57, 701
- Goetz, 2005, Mov Disord, 20, 523, 10.1002/mds.20464 · DOI · Paper page
- Henchcliffe, 2005, Expert Rev Neurother, 5, 811, 10.1586/14737175.5.6.811 · doi:10.1586/14737175.5.6.811
- Deuschl, 2006, N Engl J Med, 355, 896, 10.1056/NEJMoa060281 · DOI · Paper page
- Horstink, 2006, Eur J Neurol, 13, 1170, 10.1111/j.1468-1331.2006.01547.x · DOI · Paper page
- Watts, 2007, Neurology, 68, 272, 10.1212/01.wnl.0000252355.79284.22 · DOI · Paper page
- Mahmood, 1997, Clin Pharmacokinet, 33, 91, 10.2165/00003088-199733020-00002 · DOI
- Mercuri, 1997, J Neurosci, 17, 2267, 10.1523/JNEUROSCI.17-07-02267.1997 · DOI
- Goetz, 2006, Neurology, 66, 1427, 10.1212/01.wnl.0000210692.95595.1c · doi:10.1212/01.wnl.0000210692.95595.1c
- Clarke, 2005, Lancet, 365, 914, 10.1016/S0140-6736(05)71056-4 · doi:10.1016/s0140-6736(05)71056-4
- Demarcaida, 2006, Mov Disord, 21, 1716, 10.1002/mds.21048 · doi:10.1002/mds.21048
- Shin, 1997, Drug Metab Dispos, 25, 657
- Cedarbaum, 1991, Clin Neuropharmacol, 14, 228, 10.1097/00002826-199106000-00005 · DOI
- Shoulson, 2002, Ann Neurol, 51, 604, 10.1002/ana.10191 · DOI · Paper page
- Palhagen, 2006, Neurology, 66, 1200, 10.1212/01.wnl.0000204007.46190.54 · DOI · Paper page
- 1993, NEngl J Med, 328, 176, 10.1056/NEJM199301213280305 · DOI · Paper page
- Clarke, 2006, Therapy, 3, 349
- Lew, 2005, Expert Rev Neurother, 5, 705, 10.1586/14737175.5.6.705 · DOI
- Zhang, 2002, Clin Pharmacokinet, 41, 661, 10.2165/00003088-200241090-00003 · DOI · Paper page
- Fuh, 1997, Clin Neurol Neurosurg, 99, 106, 10.1016/S0303-8467(97)80006-6 · doi:10.1016/s0303-8467(97)80006-6 · Paper page
- Clarke, 2003, J Neural Transm, 110, 1241, 10.1007/s00702-003-0036-4 · doi:10.1007/s00702-003-0036-4
- Heikkinen, 2001, Clin Neuropharmacol, 24, 150, 10.1097/00002826-200105000-00006 · DOI
- Nyholm, 2006, Clin Pharmacokinet, 45, 109, 10.2165/00003088-200645020-00001 · DOI · Paper page
- Olanow, 2000, Arch Neurol, 57, 263, 10.1001/archneur.57.2.263 · DOI · Paper page
- Factor, 2001, Clin Neuropharmacol, 24, 295, 10.1097/00002826-200109000-00007 · DOI
- Luginger, 2000, Mov Disord, 15, 873, 10.1002/1531-8257(200009)15:5<873::AID-MDS1017>3.0.CO;2-I · DOI · Paper page
- Snow, 2000, Clin Neuropharmacol, 23, 82, 10.1097/00002826-200003000-00004 · DOI · Paper page
- Verhagen Metman, 1998, Amino Acids, 14, 75, 10.1007/BF01345246 · DOI
- Verhagen Metman, 1998, Neurology, 50, 1323, 10.1212/WNL.50.5.1323 · DOI · Paper page
- Bonnet, 1995, Mov Disord, 10, 668, 10.1002/mds.870100522 · DOI
- Tintner, 2005, Arch Neurol, 62, 1290, 10.1001/archneur.62.8.1290 · DOI
- Hayashi, 1998, Intern Med, 37, 444, 10.2169/internalmedicine.37.444 · doi:10.2169/internalmedicine.37.444
- Woitalla, 2004, J Neural Transm Suppl, 68, 89, 10.1007/978-3-7091-0579-5_10 · doi:10.1007/978-3-7091-0579-5_10
- Lieberman, 1997, Neurology, 49, 162, 10.1212/WNL.49.1.162 · DOI · Paper page
- Lieberman, 1998, Neurology, 51, 1057, 10.1212/WNL.51.4.1057 · DOI · Paper page
- Whone, 2003, Ann Neurol, 54, 93, 10.1002/ana.10609 · DOI · Paper page
- Jankovic, 2007, Arch Neurol, 64, 676, 10.1001/archneur.64.5.676 · DOI
- Kenney, 2007, Expert Opin Pharmacother, 8, 1329, 10.1517/14656566.8.9.1329 · DOI
- Kolls, 2006, Clin Neuropharmacol, 29, 292, 10.1097/01.WNF.0000220824.57769.E5 · DOI
- Dewey Jr, 2001, Arch Neurol, 58, 1385, 10.1001/archneur.58.9.1385 · doi:10.1001/archneur.58.9.1385
- Schade, 2007, N Engl J Med, 356, 29, 10.1056/NEJMoa062222 · DOI · Paper page
- Zanettini, 2007, NEngl J Med, 356, 39, 10.1056/NEJMoa054830 · DOI · Paper page
- Lu, 2006, Arch Neurol, 63, 298, 10.1001/archneur.63.2.298-a · DOI
- Nirenberg, 2006, Mov Disord, 21, 524, 10.1002/mds.20757 · DOI · Paper page
- Stocchi, 2005, Lancet Neurol, 4, 590, 10.1016/S1474-4422(05)70177-0 · DOI
- 2005, Prescrire Int, 14, 224
- Driver-Dunckley, 2003, Neurology, 61, 422, 10.1212/01.WNL.0000076478.45005.EC · DOI · Paper page
- Homann, 2002, BMJ, 324, 1483, 10.1136/bmj.324.7352.1483 · DOI
- Etminan, 2003, Drug Saf, 26, 439, 10.2165/00002018-200326060-00005 · DOI
- 1999, N Engl J Med, 340, 757, 10.1056/NEJM199903113401003 · DOI · Paper page
- Durif, 2004, Neurology, 62, 381, 10.1212/01.WNL.0000110317.52453.6C · DOI · Paper page
- Diamond, 2006, Expert Rev Neurother, 6, 1181, 10.1586/14737175.6.8.1181 · DOI
Cited by
Parkinson's disease: clinical features and diagnosis
Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720
Self-citationThe clinical symptoms of Parkinson's disease.
Sveinbjornsdottir, S. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13691 · Cited by 1,410
Molecular mechanisms of L-DOPA-induced dyskinesia
Jenner, P. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2471 · Cited by 523
Neuroprotective effects of hydrogen sulfide on Parkinson’s disease rat models
Hu, L., Lu, M., Tiong, C. X., Dawe, G. S., Hu, G., & Bian, J. (2010) · Aging Cell · doi:10.1111/j.1474-9726.2009.00543.x · Cited by 365
Jin, H., Kanthasamy, A., Ghosh, A., Anantharam, V., Kalyanaraman, B., & Kanthasamy, A. G. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.09.007 · Cited by 361
Metadata
- Authors
- Jankovic, J., & Stacy, M.
- Venue
- CNS Drugs
- Published
- 2007
- Volume
- 21
- Issue
- 8
- Pages
- 677-692
- ISSN
- 1172-7047 (ISSN-L)
- OpenAlex
- W1977567629
- Cited by
- 213
- References
- 4
- FWCI
- 10.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Medical Management of Levodopa-Associated Motor Complications in Patients with Parkinson???s Disease. https://app.cochat.ai/papers/10.2165/00023210-200721080-00005
- The paper
- Jankovic, J., & Stacy, M. (2007). Medical Management of Levodopa-Associated Motor Complications in Patients with Parkinson???s Disease. CNS Drugs. https://doi.org/10.2165/00023210-200721080-00005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.